Immunocore, an Oxford-based biotech company in which Irish life-sciences investment company Malin has a 10 per cent stake, has raised more than $130 million (€120 million) in a Series B funding round. Malin invested $80 in Immunocore in July 2015 and the company is one of just four key assets in which it still has stakes. Malin took a 33 per cent stake in Poseida in late 2015 in a deal valued at $30 million. Malin raised €330 million selling shares at €10 each in its initial public offering in March 2015. Early backers included the so-called “Oxford Oracle” investment manager Neil Woodford, who held a 23 per cent stake in the listed company through Woodford Equity Income Fund.

Source: The Irish Times March 18, 2020 18:20 UTC